World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
87
Citations
33012
World Ranking
13517
National Ranking
6874

Franco M. Muggia publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Franco M. Muggia sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 663 publications — 78th percentile

78% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Franco M. Muggia D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Franco M. Muggia sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 87 D-Index — 34th percentile

34% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Franco M. Muggia was affiliated with New York University in the United States. Their academic work primarily focused on the field of Medicine, with specific contributions to Oncology and related subfields such as Reproductive Medicine, Pulmonary and Respiratory Medicine, Molecular Biology, and Epidemiology.

The research topics covered by Muggia included ovarian cancer diagnosis and treatment, endometrial and cervical cancer treatments, BRCA gene mutations in cancer, cancer immunotherapy and biomarkers, pancreatic and hepatic oncology research, PARP inhibition in cancer therapy, and cancer risks and factors.

Among their recent papers were:

  • "Phase I and pharmacokinetic study of veliparib, a PARP inhibitor, and pegylated liposomal doxorubicin (PLD) in recurrent gynecologic cancer and triple negative breast cancer with long-term follow-up" (2020, Cancer Chemotherapy and Pharmacology)
  • "History of intraperitoneal platinum drug delivery for ovarian cancer and its future applications" (2021, Cancer Drug Resistance)
  • "Temporal trends of subsequent breast cancer among women with ovarian cancer: a population-based study" (2020, Archives of Gynecology and Obstetrics)
  • "Breast radiation-associated secondary malignancies: A review" (2023, Clinical Surgical Oncology)
  • "Addressing Resistance to Targeted Therapies in Metastatic Colorectal Cancer" (2021, ONCOLOGY)

Frequent co-authors in their work included:

  • Genitourinary Cancer
  • Julie Vose
  • Howard S. Höchster
  • Robert A. Figlin
  • Tanios Bekaii-Saab

Muggia published regularly in several venues, with the most frequent being:

  • ONCOLOGY
  • SSRN Electronic Journal
  • Gynecologic Oncology
  • Current Problems in Cancer Case Reports
  • Cancer Chemotherapy and Pharmacology

Best Publications

  • Risk factors for doxorubicin-induced congestive heart failure.

    Von Hoff Dd;Layard Mw;Basa P;Davis Hl

  • Prognostic Factors for Stage III Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study

    William E. Winter;G. Larry Maxwell;Chunqiao Tian;Jay W. Carlson

  • Phase III Randomized Study of Cisplatin Versus Paclitaxel Versus Cisplatin and Paclitaxel in Patients With Suboptimal Stage III or IV Ovarian Cancer: A Gynecologic Oncology Group Study

    Franco M. Muggia;Patricia S. Braly;Mark F. Brady;Gregory Sutton

  • Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

    F M Muggia;J D Hainsworth;S Jeffers;P Miller

  • The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomized phase III trial. Gastrointestinal Tumor Study Group.

    N Petrelli;H O Douglass;L Herrera;D Russell

  • Pegylated liposomal doxorubicin (doxil): Reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2

    T. Safra;F. Muggia;S. Jeffers;D. D. Tsao-Wei

  • Toxic effects of cis-dichlorodiammineplatinum(II) in man.

    Von Hoff Dd;Schilsky R;Reichert Cm;Reddick Rl

  • Cis-diamminedichloroplatinum (II): A New Anticancer Drug

    Rozencweig M;von Hoff Dd;Slavik M;Muggia Fm

  • Daunomycin-induced cardiotoxicity in children and adults: A review of 110 cases

    Daniel D. Von Hoff;Marcel Rozencweig;Maxwell Layard;Milan Slavik

  • Liposomal doxorubicin: antitumor activity and unique toxicities during two complementary phase I studies.

    Beatrice Uziely;Susan Jeffers;Rut Isacson;Kimberlea Kutsch

  • Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil®): possible role in hypersensitivity reactions

    Asher Chanan-Khan;J. Szebeni;S. Savay;L. Liebes

  • Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study.

    C G Leichman;T R Fleming;F M Muggia;C M Tangen

  • Protective effect of the bispiperazinedione ICRF-187 against doxorubicin-induced cardiac toxicity in women with advanced breast cancer.

    James L. Speyer;Michael D. Green;Elissa Kramer;Mariano Rey

  • Trabectedin Plus Pegylated Liposomal Doxorubicin in Recurrent Ovarian Cancer

    Bradley J. Monk;Thomas J. Herzog;Stanley B. Kaye;Carolyn N. Krasner

  • Tumor Residual After Surgical Cytoreduction in Prediction of Clinical Outcome in Stage IV Epithelial Ovarian Cancer: A Gynecologic Oncology Group Study

    William E. Winter;G. Larry Maxwell;Chunqiao Tian;Michael J. Sundborg

  • Immediate adjuvant chemotherapy versus observation with treatment at relapse in pathological stage II testicular cancer.

    Williams Sd;Stablein Dm;Einhorn Lh;Muggia Fm

  • Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention.

    Janos Szebeni;Franco Muggia;Alberto Gabizon;Yechezkel Barenholz

  • The Modulation of Fluorouracil With Leucovorin in Metastatic Colorectal Carcinoma A Prospective Randomized Phase III Trial

    Nicholas Petrelli;Harold O. Douglass;Lemuel Herrera;David Russell

  • Mechanisms of proteasome inhibitor PS-341-induced G(2)-M-phase arrest and apoptosis in human non-small cell lung cancer cell lines.

    Yi He Ling;Leonard Liebes;Jian Dong Jiang;James F. Holland

  • Development of tumor-infiltrating lymphocytes in breast cancer after neoadjuvant paclitaxel chemotherapy.

    S. Demaria;M. D. Volm;R. L. Shapiro;H. T. Yee

Frequent Co-Authors

Howard S. Hochster
Howard S. Hochster Yale University
Silvia C. Formenti
Silvia C. Formenti Cornell University
Daniel D. Von Hoff
Daniel D. Von Hoff Translational Genomics Research Institute
Sylvia Adams
Sylvia Adams New York University
Joseph A. Sparano
Joseph A. Sparano Albert Einstein College of Medicine
Alberto Gabizon
Alberto Gabizon Shaare Zedek Medical Center
Sridhar Mani
Sridhar Mani Albert Einstein College of Medicine
Susan Groshen
Susan Groshen University of Southern California
Hope S. Rugo
Hope S. Rugo University of California, San Francisco
Martine Piccart
Martine Piccart Université Libre de Bruxelles

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re considering a career in medicine but seeking alternative or accelerated routes, exploring online healthcare degrees can expand your options. Many programs now offer the flexibility and convenience to balance studies with personal and professional commitments.

Aspiring nurse leaders can benefit from the shortest dnp program options, providing a faster pathway to advanced clinical roles. Those looking for the quickest entry into nursing may consider a 9 month lpn program, which opens doors to practical nursing opportunities in less than a year.

For individuals interested in mental health, pursuing a fast track mental health nursing degree can lead to in-demand roles as a nurse practitioner specializing in psychiatric care. Alternatively, if you’re drawn to healthcare leadership, healthcare administration degrees offer a route to management and administrative positions within the medical field.

With a wide range of fast, flexible, and affordable online programs, you can tailor your medical career pathway to meet your goals and lifestyle.

Best Scientists Citing Franco M. Muggia